ArticleScientific reports2026
Anti-trypanosomal, anti-inflammatory, and neuroprotective effects of Cichorium intybus sesquiterpene lactones in experimental Trypanosoma evansi infection.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trypanosoma evansi is an important protozoan pathogen affecting various animal species particularly camels and horses, leading to significant economic losses. The ineffective control of T. evansi is attributed to the absence of vaccines and emergence of resistance towards existing chemotherapeutic agents. This study evaluated the efficacy of a fraction enriched with sesquiterpene lactones derived from Cichorium intybus on parasitemia levels and related pathological changes in Trypanosoma evansi-infected rats. Eighty healthy male albino rats were allocated into four groups of equal size; Group I served as the control negative (uninfected). Group II received an intraperitoneal infection with Trypanosoma evansi (1 × 10⁴ trypanosomes/rat). Group III was also infected and received intramuscular treatment with diminazene aceturate (7 mg/kg body weight). Group IV administered a daily oral dose of C. intybus fraction (200 mg/kg body weight) and similarly infected. Infection by T. evansi induced anemia (normocytic normochromic), leucocytosis, alterations in lipid profile, and hypoglycemia. Furthermore, the infection resulted in the upregulation of interleukin-1β (IL-1β) and interleukin-6 (IL-6), alongside the downregulation of transforming growth factor-beta (TGF-β) and interleukin-10 (IL-10) gene expression levels. The pathological lesions in the splenic and brain tissues, coupled with a significant increase in brain acetylcholinesterase (AChE) activity and oxidative stress, were also observed in the infected groups. Cichorium intybus fraction administration significantly reduced the parasitemia level and alleviated the pathological changes caused by T. evansi compared to the untreated infected group. The sesquiterpene lactones- enriched fraction from C. intybus demonstrates a notable anti-trypanosomal efficacy and may represent a promising source for the development of novel trypanocidal compounds.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.